Results of the Phase III SAKK 35/03 Trial of Rituximab Maintenance for a Maximum of 5 Years in Follicular Lymphoma
Taverna CJ et al. Rituximab maintenance treatment for a maximum of 5 years in follicular lymphoma: Results of the randomized Phase III trial SAKK 35/03. Proc ASH 2013; Abstract 508.
Dr Evens is Professor of Medicine and Chief of the Division of Hematology/Oncology at Tufts Medical Center and Director of the Lymphoma Program and Interim Director at Tufts Cancer Center in Boston, Massachusetts.
|